PURPOSE: Caveolin-1 is a major structural component of caveolae, which are plasma membrane microdomains implicated in the regulation of intracellular signaling pathways. Previous studies of the expression and function of caveolin-1 in cancer have shown controversial results, indicating that the physiological role of caveolin-1 varies according to cancer type. We evaluated caveolin-1 expression in renal cell carcinoma and investigated its association with pathological features and clinical outcome. MATERIALS AND METHODS: Caveolin-1 expression was evaluated by immunohistochemistry using rabbit polyclonal antibody against caveolin-1 in 60 paraffin embedded primary renal cell carcinoma specimens and 6 metastatic renal cell carcinoma specimens. When more than 50% of all cancer cell cytoplasm stained, the tumor was considered caveolin-1 positive. Associations between caveolin-1 expression, and pathological features and clinical outcomes were analyzed. RESULTS: Of 60 primary tumors 16 (26.7%) and 5 of 6 metastatic tumors (83.3%) were immunoreactive in more than 50% of cancer cells and considered caveolin-1 positive. Although no significant associations between caveolin-1 expression, pathological stage (T stage) and distant metastasis at initial presentation were observed, significant associations between positive caveolin-1 expression and high grade tumor (p = 0.0009) and regional lymph node metastasis at initial presentation (p = 0.0049) and venous invasion (p = 0.0195) were observed. There was no difference in cancer specific survival between caveolin-1 positive and negative groups. However, in 43 patients without metastasis to regional lymph nodes or a distant site at initial presentation (N0M0) the caveolin-1 positive group had significantly shorter progression-free survival than the caveolin-1 negative group (p = 0.0332). CONCLUSIONS: Caveolin-1 over expression could be a common finding in aggressive forms of renal cell carcinoma. Caveolin-1 might have an important role in the invasion and metastatic progression of renal cell carcinoma.
PURPOSE:Caveolin-1 is a major structural component of caveolae, which are plasma membrane microdomains implicated in the regulation of intracellular signaling pathways. Previous studies of the expression and function of caveolin-1 in cancer have shown controversial results, indicating that the physiological role of caveolin-1 varies according to cancer type. We evaluated caveolin-1 expression in renal cell carcinoma and investigated its association with pathological features and clinical outcome. MATERIALS AND METHODS:Caveolin-1 expression was evaluated by immunohistochemistry using rabbit polyclonal antibody against caveolin-1 in 60 paraffin embedded primary renal cell carcinoma specimens and 6 metastatic renal cell carcinoma specimens. When more than 50% of all cancer cell cytoplasm stained, the tumor was considered caveolin-1 positive. Associations between caveolin-1 expression, and pathological features and clinical outcomes were analyzed. RESULTS: Of 60 primary tumors 16 (26.7%) and 5 of 6 metastatic tumors (83.3%) were immunoreactive in more than 50% of cancer cells and considered caveolin-1 positive. Although no significant associations between caveolin-1 expression, pathological stage (T stage) and distant metastasis at initial presentation were observed, significant associations between positive caveolin-1 expression and high grade tumor (p = 0.0009) and regional lymph node metastasis at initial presentation (p = 0.0049) and venous invasion (p = 0.0195) were observed. There was no difference in cancer specific survival between caveolin-1 positive and negative groups. However, in 43 patients without metastasis to regional lymph nodes or a distant site at initial presentation (N0M0) the caveolin-1 positive group had significantly shorter progression-free survival than the caveolin-1 negative group (p = 0.0332). CONCLUSIONS:Caveolin-1 over expression could be a common finding in aggressive forms of renal cell carcinoma. Caveolin-1 might have an important role in the invasion and metastatic progression of renal cell carcinoma.
Authors: Bo Song; Jian-Wu Tang; Bo Wang; Xiao-Nan Cui; Li Hou; Lu Sun; Li-Min Mao; Chun-Hui Zhou; Yue Du; Li-Hui Wang; Hua-Xin Wang; Ren-Shu Zheng; Lei Sun Journal: World J Gastroenterol Date: 2005-03-14 Impact factor: 5.742
Authors: Yi Wang; Olga Roche; Chaoying Xu; Eduardo H Moriyama; Pardeep Heir; Jacky Chung; Frederik C Roos; Yonghong Chen; Greg Finak; Michael Milosevic; Brian C Wilson; Bin Tean Teh; Morag Park; Meredith S Irwin; Michael Ohh Journal: Proc Natl Acad Sci U S A Date: 2012-03-12 Impact factor: 11.205
Authors: Daniel P Hall; Nicholas G Cost; Shailaja Hegde; Emily Kellner; Olga Mikhaylova; Yiwen Stratton; Birgit Ehmer; William A Abplanalp; Raghav Pandey; Jacek Biesiada; Christian Harteneck; David R Plas; Jarek Meller; Maria F Czyzyk-Krzeska Journal: Cancer Cell Date: 2014-11-10 Impact factor: 31.743
Authors: Sandra Steffens; Andres J Schrader; Hanna Blasig; Gesa Vetter; Hendrik Eggers; Wolfgang Tränkenschuh; Markus A Kuczyk; Jürgen Serth Journal: BMC Urol Date: 2011-12-07 Impact factor: 2.264
Authors: Min Lin; Melinda M DiVito; Sofia D Merajver; Madanamohan Boyanapalli; Kenneth L van Golen Journal: Mol Cancer Date: 2005-06-21 Impact factor: 27.401